Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02798692
Recruitment Status : Completed
First Posted : June 14, 2016
Last Update Posted : April 3, 2018
Sponsor:
Collaborator:
Centre for Vaccinology Ghent - CEVAC
Information provided by (Responsible Party):
Hookipa Biotech

Brief Summary:
The objectives of this first-in-human is to evaluate the safety and the immunogenicity of three administrations of a bivalent vaccine candidate against human cytomegalovirus, at three different dose levels.

Condition or disease Intervention/treatment Phase
Cytomegalovirus Infection Biological: Low dose HB-101 Biological: Medium dose HB-101 Biological: High dose HB-101 Biological: Placebo Phase 1

Detailed Description:

Hookipa Biotech AG is developing a replication-deficient lymphocytic choriomeningitis virus (rLCMV) vector platform. HB-101 is a bivalent vaccine containing two recombinant, replication-deficient lymphocytic choriomeningitis virus (rLCMV) vectors, one expressing the pp65 protein of the human cytomegalovirus (HCMV) and one expressing the gB protein of human cytomegalovirus (HCMV).

This Phase 1 will enroll three successive cohorts of 18 healthy volunteers. Each cohort will receive either a low dose, a middle dose or a high dose of the vaccine (n=14 volunteers), or placebo (n=4). A DSMB will review the safety data for the low dose cohort, before progressing to the middle, and so before high dose. Eight DSMB meetings have been planned for the whole study.

The subjects will be followed up to 12 months post first administration.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized, Placebo-controlled, Double-blind Phase I Dose-escalating Trial to Evaluate the Safety and Immunogenicity of a Vaccine Against Human Cytomegalovirus
Actual Study Start Date : June 2016
Actual Primary Completion Date : May 2017
Actual Study Completion Date : March 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Low dose HB-101 group
Intervention:Three administrations of a low dose of HB-101
Biological: Low dose HB-101
Three intra muscular administrations at Day 0, Month 1 and Month 3

Active Comparator: Medium dose HB-101 group
Intervention:Three administrations of a middle dose of HB-101.
Biological: Medium dose HB-101
Three intra muscular administrations at Day 0, Month 1 and Month 3

Active Comparator: High dose HB101 group
Intervention:Three administrations of a high dose of HB-101.
Biological: High dose HB-101
Three intra muscular administrations at Day 0, Month 1 and Month 3

Placebo Comparator: Placebo group
Intervention:Three administrations of placebo (diluent)
Biological: Placebo
Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.




Primary Outcome Measures :
  1. Safety primary outcome (local solicited symptoms) [ Time Frame: Day 0 to Day 7 after each administration ]
    Local solicited symptoms will be assessed by diary card and scripted questions for 7 days after each administration: administration site pain, induration, erythema, pruritus and swelling

  2. Safety primary outcome (general solicited symptoms) [ Time Frame: Day 0 to Day 7 after each administration ]
    General solicited symptoms will be assessed by diary card and scripted questions for 7 days after each administration: malaise, fatigue, body temperature (measured axillary), generalized myalgia.

  3. Safety primary outcome (Unsolicited AE´s) [ Time Frame: From Day 0 to Month 4 ]
    Unsolicited AEs will be recorded through open-ended general inquiries

  4. Safety primary outcome (SAEs and pregnancies) [ Time Frame: From Day 0 to Month 12 ]
    SAEs and pregnancies will be recorded during the whole study

  5. Safety primary outcome (Vital signs) [ Time Frame: From Day 0 to Month 12 ]
    Vital signs (blood pressure, heart rate and body temperature)

  6. Safety primary outcome (physical examination) [ Time Frame: From Day 0 to Month 12 ]
    general evaluation based on the Investigator judgment and local evaluation of the administration site

  7. Safety primary outcome (Clinical evaluation - part I) [ Time Frame: From Day 0 to Month 12 ]
    Complete blood count

  8. Safety primary outcome (Clinical evaluation - part II) [ Time Frame: From Day 0 to Month 12 ]
    Comprehensive Metabolic Panel


Secondary Outcome Measures :
  1. Humoral Immunogenicity [ Time Frame: From Day 0 to Month 12 ]
    • Human cytomegalovirus (HCMV) gB immunoglobulin G (IgG) by enzyme-linked immunosorbent assay (ELISA)
    • HCMV neutralization on MRC-5 cells
    • HCMV neutralization on ARPE-19 cells (depending on neutralization assay results in MRC-5 cells)
    • Lymphocytic choriomeningitis virus (LCMV) neutralization on ARPE-19 cells

  2. Cellular Immunogenicity [ Time Frame: From Day 0 to Month 12 ]
    • LCMV NP-specific interferon γ (IFN-γ) Enzyme-Linked Immunospot Assay (ELISPOT)
    • LCMV NP-specific intracellular cytokine staining (ICS) of CD4+ and CD8+ T cells for IFN-γ, IL-2, TNF-α, CD107a and CD40L
    • HCMV pp65-specific IFN-γ ELISPOT
    • HCMV gB-specific IFN-γ ELISPOT
    • HCMV pp65-specific ICS of CD4+ and CD8+ T cells for IFN-γ, IL-2, TNF-α, CD107a and CD40L
    • HCMV gB-specific ICS of CD4+ and CD8+ T cells for IFN-γ, IL-2, TNF-α, CD107a and CD40L



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Male or female, aged 18-45 years, in good health.
  • Negative for HCMV
  • Body mass index between 19 and 32 kg/m²
  • Willing to forego receipt of other routine vaccinations (with the exception of seasonal influenza vaccination) for five months after study entry.
  • For female volunteers: use of effective birth control for at least 2 months prior to study entry and willing to use effective birth control measures up to the Month 12 visit
  • Comply with the requirements of this protocol (e.g. return for follow-up visits), as judged by the Investigator.

Exclusion Criteria:

  • Works as a childcare provider.
  • Pregnant or breastfeeding woman.
  • Any screening safety laboratory value that is 2 times above the upper limit of normal value.
  • Any confirmed or suspected immunodeficiency or autoimmune disorder.
  • Treatment with any chronic immunosuppressive medication or other immuno-modifying drugs within 6 months prior to study entry. However, inhaled and topical steroids are allowed.
  • Any vaccination other than for seasonal influenza within 3 months prior to study entry.
  • Previous vaccination with an investigational HCMV vaccine.
  • Receipt of blood, blood products and/or immunoglobulins within 3 months prior to study entry.
  • History of severe allergic reactions and /or anaphylaxis
  • Allergy to any component of the vaccine preparation.
  • Expected to be unavailable to complete study follow up.
  • Tested positive for HIV, HBsAg and/or anti-HCV.
  • Participating in another clinical trial.
  • Subject with a rash, dermatological condition or tattoos in the area of the injection site, as these may interfere with administration site reaction rating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02798692


Locations
Layout table for location information
Belgium
Center for Vaccinology Ghent
Ghent, East Flanders, Belgium, 9000
Sponsors and Collaborators
Hookipa Biotech
Centre for Vaccinology Ghent - CEVAC
Investigators
Layout table for investigator information
Principal Investigator: Geert Leroux-Roels, MD PhD Prof UZ Gent

Layout table for additonal information
Responsible Party: Hookipa Biotech
ClinicalTrials.gov Identifier: NCT02798692     History of Changes
Other Study ID Numbers: H-100-001
First Posted: June 14, 2016    Key Record Dates
Last Update Posted: April 3, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Hookipa Biotech:
Prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs